nafamostat has been researched along with Acute Disease in 54 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups." | 9.15 | Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? ( Cho, M; Choi, CW; Chung, CW; Kang, DH; Kim, DU; Kim, HW; Park, KT; Park, SB; Yoon, KT, 2011) |
| "Long-term effects of nafamostat mesylate, a protease inhibitor, and imipenem, an antibiotic, on trypsintaurocholate-induced acute pancreatitis were studied in rats." | 7.70 | Long-term effects of nafamostat and imipenem on experimental acute pancreatitis in rats. ( Hayakawa, T; Ishiguro, H; Kitagawa, M; Naruse, S; Ozaki, T; Seki, Y; Wang, Y, 2000) |
| "This study was undertaken to determine whether synthetic proteinase inhibitors--nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) have any influence on multiorgan oxidant-antioxidant balance in acute haemorrhagic pancreatitis induced in Wistar rats using a retrograde intraductal injection of 5% Na-taurocholate." | 7.69 | The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis. ( Dabrowski, A; Gabryelewicz, A, 1994) |
| " infusion performed 1 h after intrabiliary injection of enterokinase/sodium taurocholate to induce acute pancreatitis (AP): (1) Saline; (2) 5 micrograms/kg/h nafamostat mesilate (FUT-175); (3) 10 micrograms/kg/h FUT-175; and (4) 25 micrograms/kg/h FUT-175." | 7.69 | Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress. ( Chui, DH; Fesce, E; Idéo, G; Marotta, F; Rezakovic, I; Suzuki, K, 1994) |
| "Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis." | 7.69 | Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995) |
| "The aim of this study was to investigate the effect of Nafamostat mesilate (FUT-175) on some blood platelet properties during the first hours of acute experimental pancreatitis (AEP) in dogs." | 7.68 | Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175). ( Bielawiec, M; Bodzenta-Lukaszyk, A; Gabryelewicz, A; Lukaszyk, A, 1992) |
| "FUT has been reported as a drug for the treatments of DIC (disseminated intravascular coagulation) and acute pancreatitis and as an anticoagulant in extracorporeal circulation." | 6.41 | [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation]. ( Tsukagoshi, S, 2000) |
| "Mizoribine has been recognized to have an acceptable toxicity profile compared with other immunosuppressants." | 5.35 | A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis. ( Ebihara, K; Mori, S, 2008) |
| "Acute pancreatitis was induced in 13 anesthetized dogs by retrograde injection of bile mixed with trypsin into the pancreatic duct." | 5.28 | Beneficial effect of therapeutic infusion of nafamostat mesilate (FUT-175) on hemodynamics in experimental acute pancreatitis. ( Babicki, A; Basinski, A; Dobosz, M; Juszkiewicz, P; Sledzinski, Z; Stanek, A; Wajda, Z, 1991) |
| " Nafamostat mesylate (nafamostat) is a drug licensed in Japan and Korea for indications including acute pancreatitis and disseminated intravascular coagulation." | 5.22 | Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review. ( Bowen, AC; Denholm, JT; Dore, GJ; Hernández-Mitre, MP; Hills, TE; Lewin, SR; McQuilten, Z; Morpeth, SC; Paterson, DL; Roberts, JA; Tong, SYC; Venkatesh, B, 2022) |
| "Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups." | 5.15 | Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? ( Cho, M; Choi, CW; Chung, CW; Kang, DH; Kim, DU; Kim, HW; Park, KT; Park, SB; Yoon, KT, 2011) |
| "This study was conducted to determine whether continuous regional arterial infusion (CRAI) of the protease inhibitor, nafamostat mesylate, in acute necrotizing pancreatitis, would reduce mortality." | 5.08 | Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. ( Kakugawa, Y; Matsuno, S; Sunamura, M; Takeda, K, 1996) |
| "The proteolytic enzyme inhibitor nafamostat mesylate is widely used for the treatment of acute pancreatitis and disseminated intravascular coagulation." | 4.31 | Identification of Risk Factors for Phlebitis in Patients Treated with Nafamostat Mesylate. ( Kawakami, Y; Kotake, K; Tahira, A, 2023) |
| "Nafamostat mesilate (NM), a synthetic broad-spectrum serine protease inhibitor, has been commonly used for treating acute pancreatitis (AP) and other inflammatory-associated diseases in some East Asia countries." | 4.31 | Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation. ( Chen, P; He, WQ; Huang, L; Liu, Y; Ren, JD; Tang, YR; Zhao, LJ, 2023) |
| "The established referred allodynia/hyperalgesia following cerulein treatment was abolished by post-treatment with nafamostat mesilate, a proteinase inhibitor, and with capsazepine, a TRPV1 antagonist, in mice." | 3.76 | The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice. ( Akashi, R; Ishikura, H; Kawabata, A; Kitamura, T; Matsumura, K; Matsunami, M; Naruse, M; Nishimura, S; Sekiguchi, F; Shinozaki, Y, 2010) |
| "We treated five patients with severe acute pancreatitis by continuous arterial infusion (CAI) of protease inhibitor, nafamostat mesilate." | 3.70 | [Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis--clinical effect of arterial injection of ulinastatin]. ( Fukui, K; Hara, A; Ichikawa, M; Ito, T; Matsukawa, H; Okuda, S; Sato, K; Seki, H; Shiraga, N; Takizawa, K; Yamataka, K; Yoshioka, M, 1998) |
| "Long-term effects of nafamostat mesylate, a protease inhibitor, and imipenem, an antibiotic, on trypsintaurocholate-induced acute pancreatitis were studied in rats." | 3.70 | Long-term effects of nafamostat and imipenem on experimental acute pancreatitis in rats. ( Hayakawa, T; Ishiguro, H; Kitagawa, M; Naruse, S; Ozaki, T; Seki, Y; Wang, Y, 2000) |
| "This study was undertaken to determine whether synthetic proteinase inhibitors--nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) have any influence on multiorgan oxidant-antioxidant balance in acute haemorrhagic pancreatitis induced in Wistar rats using a retrograde intraductal injection of 5% Na-taurocholate." | 3.69 | The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis. ( Dabrowski, A; Gabryelewicz, A, 1994) |
| "Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis." | 3.69 | Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995) |
| " infusion performed 1 h after intrabiliary injection of enterokinase/sodium taurocholate to induce acute pancreatitis (AP): (1) Saline; (2) 5 micrograms/kg/h nafamostat mesilate (FUT-175); (3) 10 micrograms/kg/h FUT-175; and (4) 25 micrograms/kg/h FUT-175." | 3.69 | Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress. ( Chui, DH; Fesce, E; Idéo, G; Marotta, F; Rezakovic, I; Suzuki, K, 1994) |
| "The effect of FUT-175, a new synthetic trypsin inhibitor, was evaluated in a lethal model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented diet (CDE diet)." | 3.68 | Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice. ( Frey, CF; Isaji, S; Ruebner, B; Stanten, R; Suzuki, M, 1992) |
| "The aim of this study was to investigate the effect of Nafamostat mesilate (FUT-175) on some blood platelet properties during the first hours of acute experimental pancreatitis (AEP) in dogs." | 3.68 | Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175). ( Bielawiec, M; Bodzenta-Lukaszyk, A; Gabryelewicz, A; Lukaszyk, A, 1992) |
| "To confirm that trypsin activity is a most important initiating factor in closed duodenal loop pancreatitis in rats, we observed the course of acute pancreatitis when trypsinogen activation was inhibited by intraduodenal infusion of a potent synthetic trypsin inhibitor (TI, nafamostat mesilate) but the other conditions were left unchanged." | 3.68 | Prevention of experimental acute pancreatitis by intraduodenal trypsin inhibitor in rat. ( Hayakawa, T; Kiriyama, S; Kitagawa, M; Kondo, T; Ono, H; Sakai, Y; Shibata, T; Sobajima, H, 1990) |
| "FUT has been reported as a drug for the treatments of DIC (disseminated intravascular coagulation) and acute pancreatitis and as an anticoagulant in extracorporeal circulation." | 2.41 | [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation]. ( Tsukagoshi, S, 2000) |
| " We investigated the ideal dosage and efficacy of nafamostat mesilate for use with ECMO in patients with acute cardiac or respiratory failure." | 1.37 | Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. ( Han, SJ; Hong, KS; Kim, HS; Kim, KI; Lee, SH; Lee, WK; Whang, SM, 2011) |
| "Mizoribine has been recognized to have an acceptable toxicity profile compared with other immunosuppressants." | 1.35 | A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis. ( Ebihara, K; Mori, S, 2008) |
| "The Japanese severity score (JSS) for acute pancreatitis was revised in 2008." | 1.35 | Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis. ( Kamei, K; Ku, Y; Kuroda, Y; Ohyanagi, H; Satoi, S; Sawa, H; Shinzeki, M; Takeyama, Y; Ueda, T; Yasuda, T, 2009) |
| "However, she died of multiple organ failure and systemic cytomegalovirus infection in the chronic stage." | 1.32 | [Fulminant myocarditis treated with percutaneous cardiopulmonary support and long-term complications: three case reports]. ( Kusaba, T; Matsumuro, A; Nakahara, Y; Nakamura, T; Sawada, S, 2004) |
| "The major cause of death in acute pancreatitis is severe infection owing to bacterial translocation." | 1.31 | Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model. ( Isaji, S; Takagi, K, 2000) |
| "Acute pancreatitis was induced in 19 anesthetized dogs by retrograde injection of bile mixed with trypsin into the pancreatic duct." | 1.28 | Synthetic antiproteases in acute pancreatitis: an experimental study. ( Babicki, A; Basiński, A; Dobosz, M; Juszkiewicz, P; Sledziński, Z; Wajda, Z, 1992) |
| "Acute pancreatitis was induced in 13 anesthetized dogs by retrograde injection of bile mixed with trypsin into the pancreatic duct." | 1.28 | Beneficial effect of therapeutic infusion of nafamostat mesilate (FUT-175) on hemodynamics in experimental acute pancreatitis. ( Babicki, A; Basinski, A; Dobosz, M; Juszkiewicz, P; Sledzinski, Z; Stanek, A; Wajda, Z, 1991) |
| "The coagulo-fibrinolytic changes after acute pancreatitis was induced by the intraductal injection of an autologous bile and trypsin mixture showed decreased platelet counts, decreased plasma fibrinogen levels, prolonged partial prothrombin time and increased fibrinogen degradation products." | 1.28 | Effect of a synthetic protease inhibitor (Fut-175) on coagulation abnormalities during experimental acute pancreatitis in dogs. ( Ha, S; Haku, A; Hiura, A; Nishiwaki, H; Satake, K; Umeyama, K, 1990) |
| " When a new synthetic antiprotease (nafamstat mesilate) in a dosage of 0." | 1.27 | Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect. ( Koh, I; Nishiwaki, H; Satake, K; Umeyama, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (12.96) | 18.7374 |
| 1990's | 24 (44.44) | 18.2507 |
| 2000's | 15 (27.78) | 29.6817 |
| 2010's | 5 (9.26) | 24.3611 |
| 2020's | 3 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Hernández-Mitre, MP | 1 |
| Tong, SYC | 1 |
| Denholm, JT | 1 |
| Dore, GJ | 1 |
| Bowen, AC | 1 |
| Lewin, SR | 1 |
| Venkatesh, B | 1 |
| Hills, TE | 1 |
| McQuilten, Z | 1 |
| Paterson, DL | 1 |
| Morpeth, SC | 1 |
| Roberts, JA | 1 |
| Kotake, K | 1 |
| Tahira, A | 1 |
| Kawakami, Y | 1 |
| Chen, P | 1 |
| Zhao, LJ | 1 |
| Huang, L | 1 |
| He, WQ | 1 |
| Tang, YR | 1 |
| Liu, Y | 1 |
| Ren, JD | 1 |
| Mori, S | 1 |
| Ebihara, K | 1 |
| Ueda, T | 1 |
| Takeyama, Y | 1 |
| Yasuda, T | 1 |
| Kamei, K | 1 |
| Satoi, S | 1 |
| Sawa, H | 1 |
| Shinzeki, M | 1 |
| Ku, Y | 1 |
| Kuroda, Y | 1 |
| Ohyanagi, H | 1 |
| Piaścik, M | 1 |
| Rydzewska, G | 2 |
| Milewski, J | 1 |
| Olszewski, S | 1 |
| Furmanek, M | 1 |
| Walecki, J | 1 |
| Gabryelewicz, A | 4 |
| Nishimura, S | 1 |
| Ishikura, H | 1 |
| Matsunami, M | 1 |
| Shinozaki, Y | 1 |
| Sekiguchi, F | 1 |
| Naruse, M | 1 |
| Kitamura, T | 1 |
| Akashi, R | 1 |
| Matsumura, K | 1 |
| Kawabata, A | 1 |
| Han, SJ | 1 |
| Kim, HS | 1 |
| Kim, KI | 1 |
| Whang, SM | 1 |
| Hong, KS | 1 |
| Lee, WK | 1 |
| Lee, SH | 1 |
| Park, KT | 1 |
| Kang, DH | 1 |
| Choi, CW | 1 |
| Cho, M | 1 |
| Park, SB | 1 |
| Kim, HW | 1 |
| Kim, DU | 1 |
| Chung, CW | 1 |
| Yoon, KT | 1 |
| Hamada, Y | 1 |
| Imaizumi, H | 2 |
| Miyazawa, S | 1 |
| Kida, M | 2 |
| Souma, K | 1 |
| Koizumi, W | 1 |
| Sunakawa, K | 1 |
| Kuroyama, M | 1 |
| Kotani, K | 1 |
| Ichiba, S | 1 |
| Andou, M | 1 |
| Sano, Y | 1 |
| Date, H | 1 |
| Tedoriya, T | 1 |
| Goto, K | 1 |
| Shimizu, N | 1 |
| Imamura, T | 1 |
| Yoshida, H | 1 |
| Ishikawa, A | 1 |
| Katayose, K | 1 |
| Nozu, F | 1 |
| Kitamura, K | 1 |
| Ikegami, A | 1 |
| Takahashi, A | 1 |
| Niikawa, J | 1 |
| Tanaka, S | 1 |
| Ishii, H | 1 |
| Hoshino, M | 1 |
| Kusano, M | 1 |
| Matsui, S | 1 |
| Hashimoto, T | 1 |
| Mitamura, K | 1 |
| Nishimaki, H | 1 |
| Okuno, J | 1 |
| Kataoka, Y | 1 |
| Kida, Y | 1 |
| Soma, K | 1 |
| Saigenji, K | 1 |
| Kusaba, T | 1 |
| Nakahara, Y | 1 |
| Matsumuro, A | 1 |
| Nakamura, T | 1 |
| Sawada, S | 1 |
| Inoue, K | 1 |
| Yoshiba, M | 1 |
| Kohsaki, T | 1 |
| Nishimori, I | 1 |
| Onishi, S | 1 |
| Takeda, K | 5 |
| Nakae, H | 1 |
| Tajimi, K | 1 |
| Iwaki, M | 2 |
| Ozeki, M | 2 |
| Sato, T | 2 |
| Suzuki, K | 2 |
| Motoyoshi, A | 2 |
| Suzuki, S | 1 |
| Fujita, M | 1 |
| Aoyama, T | 2 |
| Araida, T | 1 |
| Frey, CF | 2 |
| Ruebner, B | 2 |
| Carlson, J | 1 |
| King, J | 1 |
| Marotta, F | 1 |
| Fesce, E | 1 |
| Rezakovic, I | 1 |
| Chui, DH | 1 |
| Idéo, G | 1 |
| Nakae, Y | 1 |
| Naruse, S | 2 |
| Kitagawa, M | 3 |
| Hirao, S | 1 |
| Yamamoto, R | 1 |
| Hayakawa, T | 3 |
| Dabrowski, A | 1 |
| Kitagawa, H | 1 |
| Chang, H | 1 |
| Fujita, T | 1 |
| Morishima, I | 1 |
| Sassa, H | 1 |
| Sone, T | 1 |
| Tsuboi, H | 1 |
| Kondo, J | 1 |
| Koyama, T | 1 |
| Ogawa, M | 1 |
| Mori, Y | 1 |
| Ueda, S | 1 |
| Mori, T | 1 |
| Makino, Y | 1 |
| Hori, J | 1 |
| Ohto, M | 1 |
| Wakashin, M | 1 |
| Matsuno, S | 4 |
| Sunamura, M | 2 |
| Kakugawa, Y | 4 |
| Kawasaki, K | 1 |
| Arimura, Y | 1 |
| Hirata, H | 1 |
| Suzuki, T | 1 |
| Kakumoto, Y | 1 |
| Kaneto, H | 1 |
| Mihara, M | 1 |
| Imai, K | 1 |
| Matsukawa, H | 1 |
| Hara, A | 1 |
| Ito, T | 1 |
| Fukui, K | 1 |
| Sato, K | 1 |
| Ichikawa, M | 1 |
| Yoshioka, M | 1 |
| Seki, H | 1 |
| Yamataka, K | 1 |
| Takizawa, K | 1 |
| Okuda, S | 1 |
| Shiraga, N | 1 |
| Hongo, H | 1 |
| Takano, H | 1 |
| Imai, A | 1 |
| Yamaguchi, T | 1 |
| Boku, Y | 1 |
| Fujii, T | 1 |
| Naito, Y | 1 |
| Yoshida, N | 1 |
| Yoshikawa, T | 1 |
| Kondo, M | 1 |
| Zhang, JP | 1 |
| Blum, MG | 1 |
| Chang, AC | 1 |
| Shyr, Y | 1 |
| Blair, KS | 1 |
| Awwad, M | 1 |
| Pierson, RN | 1 |
| Tsukagoshi, S | 1 |
| Kistler, EB | 1 |
| Lefer, AM | 1 |
| Hugli, TE | 1 |
| Schmid-Schönbein, GW | 1 |
| Takagi, K | 1 |
| Isaji, S | 2 |
| Wang, Y | 1 |
| Ishiguro, H | 1 |
| Seki, Y | 1 |
| Ozaki, T | 1 |
| Nakase, H | 1 |
| Itani, T | 1 |
| Mimura, J | 1 |
| Kawasaki, T | 1 |
| Komori, H | 1 |
| Okazaki, K | 1 |
| Chiba, T | 1 |
| Hirano, T | 1 |
| Manabe, T | 1 |
| Tobe, T | 1 |
| Kashima, K | 1 |
| Kataoka, K | 1 |
| Umehara, K | 1 |
| Suzuki, M | 1 |
| Stanten, R | 1 |
| Lukaszyk, A | 1 |
| Bodzenta-Lukaszyk, A | 1 |
| Bielawiec, M | 1 |
| Yanamoto, H | 1 |
| Kikuchi, H | 1 |
| Sato, M | 1 |
| Shimizu, Y | 1 |
| Yoneda, S | 1 |
| Okamoto, S | 1 |
| Murakawa, M | 1 |
| Okamura, T | 1 |
| Shibuya, T | 1 |
| Harada, M | 1 |
| Otsuka, T | 1 |
| Niho, Y | 1 |
| Yoshida, K | 1 |
| Toki, F | 1 |
| Takeuchi, T | 1 |
| Dobosz, M | 2 |
| Sledziński, Z | 2 |
| Babicki, A | 2 |
| Juszkiewicz, P | 2 |
| Basiński, A | 2 |
| Wajda, Z | 2 |
| Stanek, A | 1 |
| Kawaguchi, S | 1 |
| Kobari, M | 3 |
| Satake, K | 2 |
| Ha, S | 1 |
| Hiura, A | 1 |
| Nishiwaki, H | 2 |
| Haku, A | 1 |
| Umeyama, K | 2 |
| Ono, H | 1 |
| Kondo, T | 1 |
| Shibata, T | 1 |
| Sakai, Y | 1 |
| Kiriyama, S | 1 |
| Sobajima, H | 1 |
| Ino, Y | 1 |
| Kurumi, M | 1 |
| Wisner, JR | 1 |
| Ozawa, S | 1 |
| Renner, IG | 1 |
| Prokopowicz, J | 1 |
| Bodzenta, A | 1 |
| Bielecki, W | 1 |
| Koh, I | 1 |
5 reviews available for nafamostat and Acute Disease
| Article | Year |
|---|---|
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.
Topics: Acute Disease; Antiviral Agents; Benzamidines; COVID-19 Drug Treatment; Fibrinolytic Agents; Guanidi | 2022 |
[Blood purification for patients with chronic renal failure accompanied by severe liver disease].
Topics: Acute Disease; Anticoagulants; Benzamidines; Carrier State; Cellulose; Chronic Disease; Dialysis Sol | 2004 |
[Treatment of acute pancreatitis with protease inhibitor, H2 receptor antagonist and somatostatin analogue].
Topics: Acute Disease; Aprotinin; Benzamidines; Cimetidine; Drug Administration Schedule; Drug Therapy, Comb | 2004 |
[Continuous regional arterial infusion of protease inhibitor and antibiotic for severe acute pancreatitis].
Topics: Acute Disease; Angiography; Anti-Bacterial Agents; Benzamidines; Clinical Trials as Topic; Guanidine | 2004 |
[Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
Topics: Acute Disease; Adult; Anticoagulants; Benzamidines; Disseminated Intravascular Coagulation; Extracor | 2000 |
4 trials available for nafamostat and Acute Disease
| Article | Year |
|---|---|
The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study.
Topics: Acute Disease; Anti-Bacterial Agents; Benzamidines; Drug Administration Schedule; Drug Therapy, Comb | 2010 |
Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
Topics: Acute Disease; Aged; Amylases; Benzamidines; Cholangiopancreatography, Endoscopic Retrograde; Dose-R | 2011 |
Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Benzamidines; Drainage; Female; Guanidines; Humans; Imi | 1996 |
Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Cerebral Angiogra | 1992 |
45 other studies available for nafamostat and Acute Disease
| Article | Year |
|---|---|
Identification of Risk Factors for Phlebitis in Patients Treated with Nafamostat Mesylate.
Topics: Acute Disease; Guanidines; Humans; Pancreatitis; Risk Factors | 2023 |
Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Ceruletide; Histone Deacetylase 6; Inflammasomes; | 2023 |
A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis.
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Benzamidines; Diabetic Ketoacidosis; Drug Therapy, Combi | 2008 |
Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis.
Topics: Acute Disease; Benzamidines; Enteral Nutrition; Female; Guanidines; Humans; Infusions, Intra-Arteria | 2009 |
The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice.
Topics: Acute Disease; Animals; Benzamidines; Capsaicin; Ceruletide; Disease Models, Animal; Gene Expression | 2010 |
Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.
Topics: Acute Disease; Anticoagulants; Benzamidines; Dose-Response Relationship, Drug; Extracorporeal Membra | 2011 |
Compatibility of carbapenem antibiotics with nafamostat mesilate in arterial infusion therapy for severe acute pancreatitis: stabilities of carbapenem antibiotics.
Topics: Acute Disease; Benzamidines; Carbapenems; Drug Stability; Guanidines; Humans; Infusions, Intra-Arter | 2012 |
Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation.
Topics: Acute Disease; Adult; Anticoagulants; Benzamidines; Combined Modality Therapy; Extracorporeal Membra | 2002 |
[A case with severe acute pancreatitis treated by regional arterial infusion of nafamostat mesilate and imipenem via both celiac artery and superior mesenteric artery].
Topics: Acute Disease; Aged; Benzamidines; Celiac Artery; Cilastatin; Cilastatin, Imipenem Drug Combination; | 2002 |
Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit.
Topics: Acute Disease; Anti-Bacterial Agents; Benzamidines; Drug Therapy, Combination; Female; Guanidines; H | 2004 |
[Fulminant myocarditis treated with percutaneous cardiopulmonary support and long-term complications: three case reports].
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Benzamidines; Cardiopulmonary Bypass; Fatal | 2004 |
Correlation between serum nafamostat mesilate and activated coagulation time during continuous hemodiafiltration.
Topics: Acute Disease; Anticoagulants; Benzamidines; Diatomaceous Earth; Female; Guanidines; Hemodiafiltrati | 2005 |
[Pharmacological studies of FUT-175, nafamstat mesilate. II. Effects on experimental acute pancreatitis].
Topics: Acute Disease; Amylases; Animals; Benzamidines; Blood Glucose; Blood Pressure; Dogs; Female; Guanidi | 1984 |
Therapeutic regimens in acute experimental pancreatitis in rats: effects of a protease inhibitor, a beta-agonist, and antibiotics.
Topics: Acute Disease; Adrenergic beta-Agonists; Amylases; Animals; Benzamidines; Diatrizoate Meglumine; Ent | 1995 |
Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress.
Topics: Acute Disease; Animals; Benzamidines; Dextrans; Fluorescein-5-isothiocyanate; Guanidines; Male; Panc | 1994 |
Activation of trypsinogen in experimental models of acute pancreatitis in rats.
Topics: Acute Disease; alpha-Macroglobulins; Animals; Benzamidines; Ceruletide; Disease Models, Animal; Guan | 1995 |
The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis.
Topics: Acute Disease; Animals; Benzamidines; Gabexate; Guanidines; Lung; Male; Malondialdehyde; Oxidative S | 1994 |
Hyperkalemia due to nafamostat mesylate.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Guanidines; Humans; Hype | 1995 |
A case of fulminant myocarditis rescued--by long-term percutaneous cardiopulmonary support.
Topics: Acute Disease; Adult; Antithrombins; Benzamidines; Complement Inactivator Proteins; Guanidines; Hear | 1994 |
Protective effects of FUT-175 on acute massive hepatic necrosis induced in mice following endotoxin injection and immunization with liver proteins.
Topics: Acute Disease; Animals; Autoimmune Diseases; Benzamidines; Chemical and Drug Induced Liver Injury; E | 1993 |
[Marked improvement of "severe acute pancreatitis" with continuous administration of protease inhibitor: nafamostat mesilate (Futhan) via intraarterial infusion in a case].
Topics: Acute Disease; Benzamidines; Guanidines; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancr | 1996 |
[Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis--clinical effect of arterial injection of ulinastatin].
Topics: Acute Disease; Adult; Benzamidines; Drug Therapy, Combination; Glycoproteins; Guanidines; Humans; In | 1998 |
Pancreatic phospholipase A2 induces bacterial translocation in rats.
Topics: Acute Disease; Animals; Bacterial Translocation; Benzamidines; Cecum; Guanidines; Injections, Intrap | 1999 |
Immunohistologic evaluation of mechanisms mediating hyperacute lung rejection, and the effect of treatment with K76-COOH, FUT-175, and anti-Gal column immunoadsorption.
Topics: Acute Disease; Animals; Benzamidines; Blood Transfusion; Complement Inactivator Proteins; Galactosid | 1999 |
Plasma activation during splanchnic arterial occlusion shock.
Topics: Acute Disease; Animals; Arterial Occlusive Diseases; Benzamidines; Biological Factors; Cats; Celiac | 2000 |
Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model.
Topics: Acute Disease; Amylases; Animals; Anti-Bacterial Agents; Bacterial Infections; Bacterial Translocati | 2000 |
Long-term effects of nafamostat and imipenem on experimental acute pancreatitis in rats.
Topics: Acute Disease; Animals; Bacterial Infections; Benzamidines; Colony Count, Microbial; Escherichia col | 2000 |
Successful treatment of severe acute pancreatitis by the combination therapy of continuous arterial infusion of a protease inhibitor and continuous hemofiltration.
Topics: Acute Disease; Aged; Benzamidines; Combined Modality Therapy; Guanidines; Hemofiltration; Humans; In | 2001 |
[The cellular and lysosomal fragility of pancreatic acinar cells after ligation of pancreatico-biliary duct in the rat and the protective effects of nafamostat mesilate].
Topics: Acute Disease; Amylases; Animals; Benzamidines; Body Water; Cathepsin B; Disease Models, Animal; Gua | 1992 |
[Treatment of acute pancreatitis].
Topics: Acute Disease; Benzamidines; Disseminated Intravascular Coagulation; Drainage; Gabexate; Glycoprotei | 1992 |
Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice.
Topics: Acute Disease; Amylases; Animals; Benzamidines; Choline; Choline Deficiency; Diet; Ethionine; Female | 1992 |
Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175).
Topics: Acute Disease; Animals; Benzamidines; Blood Platelets; Dogs; Guanidines; Male; Pancreatitis; Platele | 1992 |
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benz | 1992 |
[Antienzyme preparations in the treatment of acute pancreatitis].
Topics: Acute Disease; Adult; Aprotinin; Benzamidines; Cytidine Diphosphate Choline; Disseminated Intravascu | 1990 |
Synthetic antiproteases in acute pancreatitis: an experimental study.
Topics: Acute Disease; Animals; Benzamidines; Dogs; Gabexate; Guanidines; Hemodynamics; Hemorrhage; Pancreat | 1992 |
Beneficial effect of therapeutic infusion of nafamostat mesilate (FUT-175) on hemodynamics in experimental acute pancreatitis.
Topics: Acute Disease; Animals; Benzamidines; Dogs; Guanidines; Hemodynamics; Infusions, Intravenous; Male; | 1991 |
[Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis induced by closed duodenal loop obstruction].
Topics: Acute Disease; Animals; Benzamidines; Dogs; Guanidines; Infusions, Intra-Arterial; Necrosis; Pancrea | 1990 |
Effect of a synthetic protease inhibitor (Fut-175) on coagulation abnormalities during experimental acute pancreatitis in dogs.
Topics: Acute Disease; Animals; Benzamidines; Blood Coagulation Disorders; Blood Coagulation Factors; Blood | 1990 |
Prevention of experimental acute pancreatitis by intraduodenal trypsin inhibitor in rat.
Topics: Acute Disease; Animals; Benzamidines; Duodenum; Guanidines; Injections; Male; Pancreas; Pancreatitis | 1990 |
Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats.
Topics: Acute Disease; alpha-Macroglobulins; Animals; Benzamidines; Guanidines; Male; Pancreas; Pancreatitis | 1986 |
The effects of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat.
Topics: Acute Disease; Animals; Benzamidines; Ceruletide; Chymotrypsinogen; Guanidines; Male; Organ Size; Pa | 1989 |
Continuous arterial infusion of protease inhibitor for severe acute pancreatitis.
Topics: Acute Disease; Adult; Benzamidines; Female; Guanidines; Humans; Infusions, Intra-Arterial; Male; Mid | 1989 |
Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis.
Topics: Acute Disease; Animals; Benzamidines; Dogs; Guanidines; Infusions, Intra-Arterial; Pancreatitis; Pro | 1989 |
Effect of FUT-175 (nafamstat mesilate) on platelets in canine acute experimental pancreatitis.
Topics: Acute Disease; Animals; Benzamidines; Blood Platelets; Dogs; Guanidines; Pancreatitis; Platelet Aggr | 1988 |
Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect.
Topics: Acute Disease; Animals; Ascitic Fluid; Benzamidines; Disease Models, Animal; Dogs; Female; Guanidine | 1985 |